Iterum Therapeutics plc (ITRM)

Our Challenge

Antibiotic Resistant Infections

Every year, at least two million Americans are infected with bacteria that resist antibiotics. At least 23,000 people die as a direct result. Multi-drug resistant pathogens are a global crisis. Physicians and patients urgently need new options.

Learn More

Our Promise

New Effective Oral Treatments

Responding to specific medical need, Iterum is developing sulopenem - the first oral and IV penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative infections in both the hospital and community settings

Learn More

Tackling serious challenges, delivering unique solutions

About Us

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens.

Our Company

Careers

Our culture is defined by collaboration and a shared motivation to leverage the power of ingenuity to develop new solutions that address the ever-increasing global threat of resistant bacterial infections.